Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Control Bionics to grow accessibility tech for the disabled with $15m IPO

  • In News
  • November 25, 2020
  • Bronte Moore
Control Bionics to grow accessibility tech for the disabled with $15m IPO

Technology company, Control Bionics Limited (Proposed ASX: CBL) are one of the latest medtech companies looking to list on the exchange next month. The company is looking to raise $15m by November 25 at an offer price of $0.60 per share, giving the company an indicative market capitalization at the offer price of $50m. 

The company develops Assistive Technology (AT) which enables disabled individuals to communicate and control devices using neuroelectric signals. By using their patented Electromyography (EMG) signals, individuals with severe incapacities can use the company’s programs to operate smartphones, computers, tablets and electric wheelchairs without requiring eye tracking, keyboards, or joysticks. 

The company’s newest product offering is the wearable NeuroNode 3 which sold its first unit last year, is an upgraded version from their 2017 model. The NeuroNode uses EMG signals to operate these electric devices, thereby reducing user fatigue and increasing communication speed. The NeuroNode is registered for use here by the Therapeutics Goods Association (TGA)  and the Food and Drug Administration (FDA) in America.

The key markets for Control Bionics are Australia and Northern America, however, the company is looking to expand their reach in more states across America and begin entering the Japanese market. The company reports that each year, approximately 56,000 people are diagnosed with conditions which leave the individual with a high degree of physical incapacity such as MND, ALS, MS, and spinal cord injuries across Australia, USA, and Japan. At a unit price of around $20,000, there is a potential market opportunity of around $1.2B per year for the company.

At an offer price of $0.60, the company is not currently profitable, however, they have been able to significantly grow their revenue from $781,000 in FY19, to $3,099,000 in FY20, an increase of over 119%. Control Bionics have also seemingly not been drastically affected by COVID-19, with forecasts of the first quarter in FY2021 up 41% from the year prior. The company’s intended use of funds indicates a significant expansion plan with 43.7% of the funds raised ($6.55m) being put toward sales and marketing; and a further 20% ($3m) being allocated to Research and Development. 

Control Bionics are proposed to list on the ASX on December 7 2020. The offer is underwritten and managed by Morgans Corporate Limited.

  • About
  • Latest Posts
Bronte Moore
Bronte Moore is a business journalist at Emerald Financial whilst also completing a JD at the University of Melbourne.
Latest posts by Bronte Moore (see all)
  • This small biotech is the definition of a quiet achiever, here’s why it might be time to tune in - November 25, 2021
  • New CEO flags 100-day plan for Crowd Media’s conversational AI platform - October 19, 2021
  • Healthia emerges as largest physiotherapy provider with $88m acquisition, more growth still to come - September 22, 2021
  •  
  •  
  •  
  •  
  • als
  • assistive technology
  • asx cbl
  • control bionics
  • initial public offering
  • IPO
  • medtech
  • mnd
  • neuronode
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Bronte Moore
Bronte Moore is a business journalist at Emerald Financial whilst also completing a JD at the University of Melbourne.
Latest posts by Bronte Moore (see all)
  • This small biotech is the definition of a quiet achiever, here’s why it might be time to tune in - November 25, 2021
  • New CEO flags 100-day plan for Crowd Media’s conversational AI platform - October 19, 2021
  • Healthia emerges as largest physiotherapy provider with $88m acquisition, more growth still to come - September 22, 2021

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Bronte Moore
Bronte Moore is a business journalist at Emerald Financial whilst also completing a JD at the University of Melbourne.
Latest posts by Bronte Moore (see all)
  • This small biotech is the definition of a quiet achiever, here’s why it might be time to tune in - November 25, 2021
  • New CEO flags 100-day plan for Crowd Media’s conversational AI platform - October 19, 2021
  • Healthia emerges as largest physiotherapy provider with $88m acquisition, more growth still to come - September 22, 2021
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.